Introduction
Interleukin (IL)-35, the newest member of the IL-12 family, is a heterodimer composed of p35 and Epstein-Barr virus-induced gene 3 (EBI-3) subunit [1] . It is a pivotal inhibitory cytokine produced by natural, thymus-derived regulatory T (nTreg) cell populations [2] . IL-35 can suppress immune responses by inducing expansion of Treg cells and suppression of T helper (Th)17 cell development [3] . Previous studies have shown that IL-35 was significantly associated with the inflammatory response in multiple diseases such as allergic airways disease [4] , collagen-induced arthritis [5] , acute pancreatitis [6] as well as T cell-dependent colitis [7] . Studies in vitro have revealed that mice without IL-35 show inflammatory immune responses and are more likely develop diseases, such as inflammatory bowel disease and autoimmune diseases [7] [8] [9] [10] . Furthermore, increased IL-35 levels in allografts may decrease the occurrence of acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation [11] . We have previously demonstrated that IL-35 expression plasmids had suppressive potential by proliferation of Treg cells and suppression of T effector cells in a mouse transplantation model [12] . However, how to maintain the continuous and stable IL-35 levels in vivo, and the mechanism by which IL-35 influences immunosuppressive effects in mice are not completely understood. In this study, we explored the role of IL-35 using IL-35-expressing mesenchymal stem cells (MSCs) in mice.
Cell-based therapy using MSCs has great potential in immunosuppression. These multipotent cells have paracrine and immunomodulatory properties and have shown promise in treatment of several diseases including myocardial infarction, traumatic brain injury and graft-versus-host disease [13] [14] [15] . One important mechanism by which MSCs have been shown to act is by expanding the circulating population of Treg cells [16] . Moreover, MSCs have recently emerged as promising cellular vehicles for potential clinical applications [17, 18] .
In view of the immunosuppressive effects of MSCs and IL-35, we hypothesize that they can collaborate with each other to propagate the immunomodulatory and Treg cell functions, and can prevent the initiation of inflammation and subsequent allograft rejection after transplantation. We have previously shown the feasibility of IL-35 gene transfection of murine bone marrow MSCs and the effect of IL-35 gene-modified MSCs on the proliferation of Treg cells by Lipofectamine. However, we have never examined the role of IL-35 gene transduction into MSCs using lentiviral vectors. We successfully transduced murine adipocyte-derived mesenchymal stem cells (Ad-MSCs) by IL-35-harbouring lentiviral particles, and evaluated the expression of IL-35 by enzyme-linked immunosorbent assay (ELISA). We also analysed the IL-35 bioactivity and the effect of this cytokine in mice.
Materials and methods
Animals. Specific pathogen-free wild-type male C57BL/6 (H-2b) and BALB/c (H-2d) mice, aged 4-5 weeks and weighing 20-25 g were purchased from the Institute of Radiation Medicine Laboratory Animal Center (Tianjin, China). This study was approved by the Ethics Committee of Tianjin Medical University. All animal experiments were performed in accordance with the Guidelines of Institutional Animal Care and Use Committee at Tianjin medical University.
Isolation and culture of Ad-MSCs. Adipose tissue was obtained from the abdominal fat of C57BL/6 (H-2b) mice and digested with 0.075% collagenase type I (Solarbio, Beijing, China) at 37°C for 1 h. Enzyme activity was neutralized using a-modified Eagle medium (Gibco, Carlsbad, CA, USA) containing 10% foetal bovine serum (Gibco), followed by centrifugation at 200 g for 10 min. Cells were plated at 10 7 /cm 2 and incubated at 37°C in a humidified environment containing 5% CO 2 . The culture medium was replaced every 2 days. In this study, confluent third-passage cells were used.
Flow cytometry was used to analyse the MSC phenotype. Trypsinized cells (0.025% trypsin and 0.02% EDTA) were twice washed by PBS and stained according to the manufacturer's recommendations for flow cytometry. The cells were labelled with fluorescein isothiocyanate-labelled monoclonal antibodies against mouse stem cell antigen-1 (Sca-1), CD44, CD34, CD45 and CD29 (BD Biosciences Clontech, Palo Alto, CA, USA). After washing, labelled cells were analysed by flow cytometry using a BD FACS Canto II (BD Biosciences) instrument and data were analysed with BD FACSDiva software (BD Biosciences).
Mesenchymal stem cells were analysed for their capacity to differentiate into adipogenic and osteogenic lineages, as described previously [19] . For adipogenic and osteogenic differentiation, cells were plated in six-well plates at 2 9 10 4 /cm 2 and treated for 3 weeks with adipogenic and osteogenic media. Adipogenic and osteogenic differentiation was assessed by oil red O staining, as an indicator of intracellular lipid accumulation, and alizarin red S staining, as an indicator of extracellular matrix calcification.
Identification and amplification of IL-35 plasmid. IL-35-expressing plasmid vector (pSecTag2A-IL35) was provided by Glasgow Biomedical Research Centre, University of Glasgow, UK. The pSecTag2A-IL35 plasmid was successfully identified by restriction enzymes NotI and EcoRI. The murine IL-35 cDNA was amplified with PCR from plasmid pSecTag2A-IL35 by the following primer:
Forward: 5ʹCCCCGGATCCCACTGAAACAGCTCTC GTGGCTCT3ʹ Reverse: 5ʹGGCGGCGGCCGCATAG CCCATCACCCTGTTGA3ʹ Cloning of IL-35 gene and lentivirus generation. Murine IL-35 cDNA was subcloned into pCCS-Lv201 to generate the recombinant vector pCCS-IL35-Lv201. Lentivirus generation was performed using GeneCopoeia 293Ta cells, according to the instructions of the lentivirus package kit (Lenti-PacTM HIV; GeneCopoeia, Guangzhou, China). Cell culture supernatants were collected and concentrated with the Lenti-Pac concentration kit (GeneCopoeia).
Ad-MSC transduction. Adipocyte-derived mesenchymal stem cells were trypsinized and seeded at 2 9 10 4 cells in 1 ml DMEM-F12 supplemented with 10% FBS in a 24-well plate. Then, 10 ll virus solution was added in the presence of 5 lg/ml Polybrene (Sigma-Aldrich, MO, USA), followed by centrifugation for 1 min at 200 g. Six hours later, the medium was refreshed. Green fluorescent protein (GFP)-positive transduced Ad-MSCs were observed by fluorescence microscopy, with transfection rates measured by flow cytometry 72 h after transduction. IL-35 protein levels in cell supernatants were measured using the mIL-35 ELISA kit (BioLegend, San Diego, CA, USA).
Intravenous transplantation of IL-35-MSCs. To evaluate the effects of IL-35-MSCs in vivo, 500 ll purified IL-35-MSCs (10 7 cells/ml) was injected using a 26-gauge needle via the tail vein of C57BL/6 (H-2b) mice daily for 3 days. Mice were divided into three groups of six mice: (1) transfected AdMSCs group; (2) non-transfected Ad-MSCs group; and (3) PBS group. These experiments were performed three times. At 48 and 72 h post-intravenous transplantation, peripheral blood was collected and tested for IL-35 expression using the mIL-35 ELISA kit (BioLegend, San Diego, CA, USA).
One-way mixed lymphocyte reaction. Spleen mononuclear cells (2 9 10 6 /ml in 1 ml medium) were collected from BALB/c (H-2d) mice and treated with 50 lg/ml mitomycin for 30 min to obtain stimulator cells. Seven days after the last intravenous transplantation, mononuclear cells from the spleen of intravenously transplanted C57BL/6 (H-2b) mice were collected as responder cells. The stimulator and responder cell concentrations were adjusted to 2 9 10 6 /ml with RPMI-1640 medium. Coculture of responder cells from C57BL/6 mice and stimulator cells from BALB/c mice were divided into three groups: (1) IL-35-MSCs; (2) Ad-MSCs; and (3) PBS. These experiments were performed three times. After 72 h of coculture, the percentage of CD4 + T cells and CD4 + CD25 + Treg cells was assayed by flow cytometry.
Cytokine expression and bioactivity assays. After 72 h of coculture, the culture supernatants of one-way mixed lymphocyte reaction were collected and tested for IL-35 (BioLegend), IL-17A (eBioscience, San Diego, CA, USA) and IL-10 (eBioscience) expression using ELISA kits.
Statistical analysis. Data are expressed as means AE standard error of the mean. GraphPad Prism (version: 5.01) (Software Alliance, China) was used to perform all statistical analyses. One-way analysis of variance was used for group comparisons. P < 0.05 was considered statistically significant.
Results

Characterization of Ad-MSCs phenotype and differentiation
The cultured Ad-MSCs from C57BL/6 murine adipose tissues became subconfluent after 7 days and had a spindle-shaped fibroblast-like appearance, similar to previously reported adipose tissue-derived MSCs. The immunophenotypes of the Ad-MSCs were analysed by flow cytometry. Cells were negative for haematopoietic markers such as CD34 and CD45, but positive for Sca-1, CD44 and CD29. Furthermore, Ad-MSCs had the ability to differentiate into adipogenic and osteogenic lineages after culture under the appropriate conditions (Fig. 1) .
Lentiviral transduction of Ad-MSCs
Murine IL-35 gene was amplified by PCR from pSecTag2A-IL35 plasmid (a gift from professor Xiao-qing Wei of the Glasgow Biomedical Research Centre and subcloned into the lentivirus vector pCCS-Lv201 to generate the recombinant vector pCCS-IL35-Lv201 (Fig. 2A) . We successfully produced IL-35-harbouring lentiviral particles in GeneCopoeia 293Ta cells. GFP-positive transduced Ad-MSCs were observed under a fluorescence microscope, with a transduction rate of 35.7% at 72 h (Fig. 2B,C) . Total RNA was isolated from transduced Ad-MSCs, and IL-35 mRNA was successfully detected by RT-PCR (Fig. 2D ). IL-35 protein level was 350 pg/ml in transduced MSC medium as determined by ELISA. IL-35 was not detected in untransduced MSCs (Fig. 2E) . 
IL-35 expression of IL-35-MSCs in vivo
To detect the IL-35 expression of IL-35-MSCs in vivo, IL-35-MSCs, MSCs or PBS were respectively injected via the caudal vein of C57BL/6(H-2b) mice daily for 3 days. At 48 and 72 h post-intravenous transplantation, peripheral blood was collected and tested for IL-35 expression using ELISA. IL-35 level was significantly higher in the IL-35-MSC group than in the other two groups (P < 0.01) (Fig. 3) , indicating that IL-35-MSCs injection in vivo give rise to high expression of IL-35.
IL-35-MSCs increase CD4 + CD25 + Treg cells and inhibit proliferation of CD4 + T cells
To evaluate the effects of IL-35-MSCs or MSCs on murine immune function, a one-way mixed lymphocyte reaction of the intravenously transplanted mice was induced. The percentage of lymphocytes in the syngeneic control groups did not change significantly over 4 days of culture, whereas the percentage of lymphocytes in the allogeneic mixed lymphocyte groups (including the transplantation group) increased, indicating clonal proliferation of lymphocytes (Fig. 4A) . Flow cytometric analysis of the culture supernatants showed that CD4 + T lymphocytes in the allogeneic groups significantly increased, and IL-35 MSC-or MSCstimulated proliferation of CD4 + CD25 + Treg cells (Fig. 4B) inhibited the proliferation of CD4 + T cells (Fig. 4C) .
IL-35-MSCs promote immunosuppressive function
To investigate the mechanism by which IL-35-MSCs propagate immunosuppressive function, IL-10, IL-17 and IL-35 levels in culture supernatants were assessed by ELISA. The results showed increased IL-10 and IL-35 and reduced IL-17 levels secreted by the coculture system compared with the other two groups (Fig. 5) . ............................................................................................................................................................... ...
Discussion
Organ transplantation is useful for treating the end-stage of organ failure. This requires an often long dependence on non-specific immunosuppression. Treg cells maintain immune homeostasis by suppressing inflammatory responses towards self-and alloantigens [20, 21] and therefore play a vital role in allograft survival. Research in animal models has revealed that Treg-based therapies can be effective in promoting long-term tolerance to skin and heart grafts [22, 23] . IL-35 is required for maximal regulatory activity of murine Treg cells in vitro and in vivo [9] . The immunosuppressive effect of IL-35 not only is characterized by the suppression of effector T cell responses and proliferation, but also is manifested in the induction of Treg cells to generate and propagate tolerance to infection, and these Treg cells in turn secrete IL-35 to enhance the immunosuppressive effect [3, 8] .
Mesenchymal stem cells are immunomodulators and are suggested as promising therapeutic agents for several autoimmune diseases and transplantation complications [24] . Cell-based immunotherapy using MSCs can be genetically engineered without loss of differentiation capability [25] and with intrinsic immunosuppressive behaviour, which allows allogeneic transplantation [26, 27] . Previous studies have demonstrated that MSCs can be used as cellular therapeutic vehicles to deliver potent immunoregulatory factors such as tumour necrosis factor receptor [28] , IL-10 [29] and forkhead box p3 [30] , which increase the immunomodulatory effect of MSCs. In this study, we aimed to enhance the potential immunosuppressive effects by IL-35 gene-modified MSCs in mice.
Due level (pg/ml) Figure 5 Cytokine levels in the mixed lymphocyte reaction culture system. The culture supernatants were collected, and the contents of several cytokines, including IL-10, IL-17A and IL-35, were detected by ELISA. Data are mean AE SD (n = 6) and are representative of at least three independent experiments. *P < 0.05, **P < 0.01. NS, not significant; IL, interleukin; ELISA, enzyme-linked immunosorbent assay. .................................................................................................................................................................. 
